key: cord-0952265-oy6rr2ae authors: Hessel Dias, Viviane Maria de Carvalho; Tuon, Felipe Francisco; de Jesus Capelo, Patrícia; Telles, João Paulo; Castelo Branco Fortaleza, Carlos Magno; Baena, Cristina Pellegrino title: Trend analysis of carbapenem-resistant Gram-negative bacteria and antimicrobial consumption in the post-COVID-19 era, an extra challenge for healthcare institutions date: 2021-11-19 journal: J Hosp Infect DOI: 10.1016/j.jhin.2021.11.011 sha: 534cc9c17cb99e04d918ff807f8987393c79b96b doc_id: 952265 cord_uid: oy6rr2ae We analyzed the incidence density trend of the carbapenem-resistant Gram-negative bacteria in device-associated infections and antimicrobial consumption in 99 critical care facilities in a low middle-income country, between January 2019 and December 2020. Carbapenem-resistant A. baumannii (CRAB)/1,000 patient-day increased in 2020 and this finding had a strong positive correlation with the incidence density of COVID-19 by the Spearman´s test. Polymyxin consumption also increased in 2020 but without significant correlation to CRAB or COVID-19 incidence density, presumably due to empirical and untargeted prescribing as a consequence of concern about CRAB infections. These findings are a warning to infection control programmes and antimicrobial stewardship. The impact of the COVID-19 pandemic goes beyond the individual level (death and disease sequelae), causing several public health issues, including in antimicrobial resistance [1] . In Brazil, the first case of COVID-19 was reported on February 26, 2020. According to the World Health Organization's COVID-19 dashboard (https://covid19.who.int/?gclid=Cj0KCQjwtMCKBhDAARIsAG-2Eu-HciJsbL9zoQLmRuqjZ4OIipukC9SSVRWdiY-iRG9IjgB9fqxMi1YaAhKSEALw_wcB), Brazil has 10,013 cases and 278.66 deaths per 100,000 inhabitants (September 26 th , 2021), and is among the highest incidence countries for the pandemic [2] . In Paraná, a state located in southern Brazil, the first confirmed COVID-19 case was reported on March 12, 2020. Since then, according to data made available by the Brazilian One of the major concerns regarding hospitalized patients with COVID-19 is bacterial superinfections, especially in the intensive care setting and in patients using invasive devices [3] as well as in situations of outbreaks by multidrug-resistant bacteria resulting from poorer adherence to infection control practices [4] . Lower middle-income countries have higher rates of antimicrobial resistance than developed countries [5] . The pandemic and the consequent overload on health services have further affected infection control programs and antimicrobial stewardship [6] . Since publications on this subject are still limited, we aimed to analyze the trend of the incidence density of carbapenem-resistant Gram-negative bacteria (CR-GNB) in device- To calculate the incidence density of the DAIs, the specific denominator of each deviceday was used (central line-day, mechanical ventilation-day, and urinary catheter-day). The incidence density of CR-GNB/1,000 patient-day was calculated using the number of occurrences of each pathogen notified in the DAIs divided by the patient-day of the corresponding period. To calculate the DDD/1,000 patient-day, the monthly antimicrobial consumption notification was divided by the corresponding defined daily dose and then by the number of patient-day in the corresponding period. Both calculations were adjusted using the 1,000 multiplier. For trend analysis, the Joinpoint Regression available from the National Cancer Institute (https://surveillance.cancer.gov/help/joinpoint ) was applied. This is a method of time trend analysis (e.g., incidence, prevalence, survival rates) that identifies segments that best explain a trend over time using a sequence of permutation tests to select the number of join points, inflection points, or trend changes in the analyzed series and ensure that the approximate probability of the Type I error is less than the specified significance level (alpha level). In this study, the parameters set as a standard by the model were used, including the logarithmic Spearman test was used to analyze the correlation between the incidence density of CR-GNB/1,000 patient-days versus reported cases of COVID-19 per 1,000 patient-days and antimicrobial consumption in DDD per 1,000 patient-days in the AICUs. Among the 11,248 device-associated infections reported during the study period, 58% (6,515) were VAP, 23% (2,622) CLABSI, and 19% (2,111) CAUTI. CLABSI and VAP incidence density presented join points with a significant increase in the second defined segment by de model, being for CLABSI the period of Apr19-Dec20 (MPC 1.9; 95% CI 1.1-2.8; P<0.001) and for VAP the period of Nov19-Dec20 (MPC 2.1; 95% CI 1.2-2.9; P<0.001), as showed in Table I According to the trend analysis, the monthly incidence density of CRAB/1,000 patientdays ( Figure 1A ) increased significantly after April 2020 (MPC 14.2; 95% CI 10.1 -18.5; P<0.001), while CRKP/1,000 patient-day showed a gradual increase during the entire observed period, but with no change in trend (MPC 2.4; 95% CI 0.7-4.1; P=0.008). And for CRPA incidence density per 1,000 patient-days, there was no significant change in the studied period. Interestingly, some antimicrobials revealed an increasing trend in consumption in DDD/1,000 patient-day. Polymyxin B increased in the period from July to December 2020, (MPC 17.5; 95% CI 4.6-31.9; P=0.009), as did colistin from April 2020 (MPC 30.7; 95% CI 17.8-44.9; P<0.001), however, this increase did not correlate significantly with the incidence density of infections caused by CR-GNB. On the other hand, other antimicrobials showed a reduction in consumption, for example, cefepime and ceftazidime (Table I) . In Figure 1 A, B , C there is a graphical representation by Joinpoint regression of the shift in trend in the incidence density of CRAB/1,000 patient-day, VAP/1,000 mv-day and Polymyxin B in DDD/1,000 patient-day, following the curve of incidence density of new COVID-19 cases/1,000 patient-day reported per month in patients admitted to the AICU in the state of Paraná ( Figure 1D) . To investigate the possible relationship between the increased incidence density of CRAB One of the main findings of our study is that the incidence density of A. baumannii/1,000 patient-day increased significantly in 2020, and this finding had a strong positive correlation with the incidence density of COVID-19 and moderate correlation for VAP, and CLABSI. The incidence density of CRKP/1,000 patient-days showed a gradual increase during the entire observed period, but with no change in trend. Our results possibly signal persistent clonal spread of CRAB [7] with significant trend change after the COVID-19 pandemic. CRKP also showed a slight increase in the studied period but gradually, with no change of trend detected, which may also be related to clonal dissemination [8] . Violation of infection control protocols favoured by the increased workload and reduced availability of healthcare workers during the pandemic. combined with institutional inability to sustain prevention and control measures, may have contributed to this finding [4] . Increased consumption of polymyxins was observed in 2020, although it showed no significant correlation with CRAB or COVID-19 incidence density by Spearman's test. This finding may be related to the increase in empiric prescribing of this antimicrobial, presumably driven by the increase in CRAB infections increasing expectation that patients would have CRAB. Consequently, there may be increased selection pressure for microbial resistance [9] , in addition to the lack of this resource on the market forcing the use of suboptimal therapies for the treatment of these infections [10] . Some changes in the pattern of antimicrobial consumption regarding cefepime, ceftazidime, ciprofloxacin, levofloxacin and meropenem (Table I) Antimicrobial use, drugresistant infections and COVID-19 The emerging epicenter of COVID-19 pandemic Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions -New Jersey Creating political commitment for antimicrobial resistance in developing countries Apart Antimicrobial Stewardship Program, COVID-19, and Infection Control: Spread of Carbapenem-Resistant Klebsiella Pneumoniae Colonization in ICU COVID-19 Patients. What Did Not Work? Molecular epidemiology characterization of OXA-23 carbapenemase-producing Acinetobacter baumannii isolated from 8 Brazilian hospitals using repetitive sequencebased PCR Molecular epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae in different facilities in Southern Brazil Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter? Combined therapy for multi-drug-resistant acinetobacter baumannii infection -is there evidence outside the laboratory This study was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES), Ministry of Education, Brazil. None.J o u r n a l P r e -p r o o f